December 10th 2020
Two studies of trastuzumab biosimilars have improved understanding of these medicines as monotherapy and in combination with other agents in metastatic breast cancer.
December 9th 2020
Investigators explained the potential for durable antitumor efficacy in patients with human epidermal growth factor receptor 2 (HER2)-expressing or -driven tumors who have exhausted other treatment options.
November 24th 2020
GP2 peptide/G-CSF in HER2-equivocal and -positive breast cancer has shown promise.
